These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28187433)

  • 1. Doxycycline directly targets PAR1 to suppress tumor progression.
    Zhong W; Chen S; Zhang Q; Xiao T; Qin Y; Gu J; Sun B; Liu Y; Jing X; Hu X; Zhang P; Zhou H; Sun T; Yang C
    Oncotarget; 2017 Mar; 8(10):16829-16842. PubMed ID: 28187433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeting of breast and colon cancer cells by PAR1 mediated apoptosis through a novel pro-apoptotic peptide.
    Ray T; Kar D; Pal A; Mukherjee S; Das C; Pal A
    Apoptosis; 2018 Dec; 23(11-12):679-694. PubMed ID: 30196356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insight into human protease activated receptor-1 as anticancer target by molecular modelling.
    Hidayat AN; Aki-Yalcin E; Beksac M; Tian E; Usmani SZ; Ertan-Bolelli T; Yalcin I
    SAR QSAR Environ Res; 2015; 26(10):795-807. PubMed ID: 26501801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat stress-induced disruption of endothelial barrier function is via PAR1 signaling and suppressed by Xuebijing injection.
    Xu Q; Liu J; Wang Z; Guo X; Zhou G; Liu Y; Huang Q; Su L
    PLoS One; 2015; 10(2):e0118057. PubMed ID: 25693178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prohibitin is involved in the activated internalization and degradation of protease-activated receptor 1.
    Wang YJ; Guo XL; Li SA; Zhao YQ; Liu ZC; Lee WH; Xiang Y; Zhang Y
    Biochim Biophys Acta; 2014 Jul; 1843(7):1393-401. PubMed ID: 24732013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule.
    Bokoch MP; Jo H; Valcourt JR; Srinivasan Y; Pan AC; Capponi S; Grabe M; Dror RO; Shaw DE; DeGrado WF; Coughlin SR
    Biochemistry; 2018 Oct; 57(39):5748-5758. PubMed ID: 30102523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents.
    Zotti AI; Di Gennaro E; Corvino A; Frecentese F; Magli E; Perissutti E; Cirino G; Roviezzo F; Terranova-Barberio M; Iannelli F; Caliendo G; Santagada V; Fiorino F; Budillon A; Severino B
    Anticancer Agents Med Chem; 2017; 17(7):973-981. PubMed ID: 27671294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A KLK4 proteinase substrate capture approach to antagonize PAR1.
    Rabinovitch E; Mihara K; Sananes A; Zaretsky M; Heyne M; Shifman J; Aharoni A; Hollenberg MD; Papo N
    Sci Rep; 2021 Aug; 11(1):16170. PubMed ID: 34373558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells.
    Qin Y; Zhang Q; Lee S; Zhong WL; Liu YR; Liu HJ; Zhao D; Chen S; Xiao T; Meng J; Jing XS; Wang J; Sun B; Dai TT; Yang C; Sun T; Zhou HG
    Oncotarget; 2015 Dec; 6(38):40667-79. PubMed ID: 26512779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulator of G protein signaling 8 inhibits protease-activated receptor 1/Gi/o signaling by forming a distinct G protein-dependent complex in live cells.
    Lee J; Ghil S
    Cell Signal; 2016 May; 28(5):391-400. PubMed ID: 26829215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.
    Mize GJ; Wang W; Takayama TK
    Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.
    Agarwal A; Covic L; Sevigny LM; Kaneider NC; Lazarides K; Azabdaftari G; Sharifi S; Kuliopulos A
    Mol Cancer Ther; 2008 Sep; 7(9):2746-57. PubMed ID: 18790755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.
    Shi X; Gangadharan B; Brass LF; Ruf W; Mueller BM
    Mol Cancer Res; 2004 Jul; 2(7):395-402. PubMed ID: 15280447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism.
    Tantivejkul K; Loberg RD; Mawocha SC; Day LL; John LS; Pienta BA; Rubin MA; Pienta KJ
    J Cell Biochem; 2005 Oct; 96(3):641-52. PubMed ID: 16052512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly functionalized 2-oxopiperazine-based peptidomimetics: an approach to PAR1 antagonists.
    Valdivielso ÁM; Ventosa-Andrés P; Tato F; Fernández-Ibañez MÁ; Pappos I; Tsopanoglou NE; García-López MT; Gutiérrez-Rodríguez M; Herranz R
    Eur J Med Chem; 2013; 70():199-224. PubMed ID: 24158013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockage of protease-activated receptor 1 ameliorates heat-stress induced intestinal high permeability and bacterial translocation.
    Xu QL; Guo XH; Liu JX; Chen B; Liu ZF; Su L
    Cell Biol Int; 2015 Apr; 39(4):411-7. PubMed ID: 25492552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis.
    Uusitalo-Jarvinen H; Kurokawa T; Mueller BM; Andrade-Gordon P; Friedlander M; Ruf W
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1456-62. PubMed ID: 17363687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias.
    Soto AG; Smith TH; Chen B; Bhattacharya S; Cordova IC; Kenakin T; Vaidehi N; Trejo J
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3600-8. PubMed ID: 26100877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway.
    Zhong W; Chen S; Qin Y; Zhang H; Wang H; Meng J; Huai L; Zhang Q; Yin T; Lei Y; Han J; He L; Sun B; Liu H; Liu Y; Zhou H; Sun T; Yang C
    Oncotarget; 2017 Dec; 8(62):104855-104866. PubMed ID: 29285218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts.
    Strande JL; Hsu A; Su J; Fu X; Gross GJ; Baker JE
    Basic Res Cardiol; 2007 Jul; 102(4):350-8. PubMed ID: 17468933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.